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The main objective of the present work was to prepare and assess dermal delivery of tacrolimus-loaded ethosomes versus classic
liposomes. Both delivery systems were characterized for particle size, polydispersity index, and entrapment eﬃciency (EE), by
dynamic laser diﬀraction and ultraﬁltration or dialysis methods, respectively. The results indicated that presence of ethanol in
the formulations aﬀected the particle size. In addition, ultraﬁltration method was selected to determine EE due to relatively short
periodascomparedwithdialysismethod.EthosomesexhibitedasigniﬁcanthigherEEandamountofdrugindermisincontrastto
classic liposomes suggesting that ethosomes with higher entrapment capacity prompted more amount of tacrolimus to permeate
through stratum corneum and reach the target of atopic dermatitis (AD). Physical stability was very well for tacrolimus-loaded
ethosomes under storage condition (4◦C). Our results demonstrated that the ethosomal system might be a promising candidate
for dermal delivery of tacrolimus for AD.
1.Introduction
Tacrolimus (C44H69NO12; MW: 822.05) with a 23-mem-
ber macrolide lactone is discovered from Streptomyces
tsukubaensis. As a potent immunosuppressor, tacrolimus
inhibitstheenzymecalcineurinphosphatasewhichcausesan
inhibition of transcription of the IL-2 gene, leading to pre-
vention of the T-lymphocyte response [1–3] without some
side eﬀects of steroids including cutaneous atrophy, striae,
and adrenal suppression [4]. Based on this mechanism,
tacrolimus has proven to be eﬃcient for the therapy of either
atopic dermatitis (AD) [5, 6] or psoriasis [7–9]. Protopic
ointment (Astellas Pharma, USA), the ﬁrst commercial
product of tacrolimus launched for the therapy of AD, was
approved in 2002. However, this commercial ointment was
reported to be related with high individual variation in mean
disposition half-life (t1/2)[ 10], the skin irritation such as
itching and skin burning with subsequent redness and pain
[11], unacceptable greasiness or stickiness and not being
water washable with subsequent uneasy feel to the patients,
and the ﬁnite ability to release drug to the skin because of
theintrinsicpropertyofointmentvehicles[12].Moreimpor-
tantly, currently available commercial formulation does not
insure adequate topical delivery of the drug into deeper skin
layers when applied on skin lesions due to the fact that the
maintargetfortacrolimusisthedermiswithitslymphocytes.
Therefore, it is highly challenging to overcome the skin
barrier stratum corneum (SC) and reach the dermis in
suﬃcient active drug concentrations. These ﬁndings prompt
for development of novel dermal delivery system permeating
the skin barrier and reaching eﬀectively the site of AD.
As an attractive and innovatory vesicular system, etho-
somehasappearedintheﬁeldofdrugdeliveryinrecentyears
[13]. Presenting attractive features correlated with its high
deformability, ethosomes could transport active agents more
eﬀectively through the stratum corneum into the deeper lay-
ers of the skin than classical liposomes [13], which was criti-
cally important to the vector applied topically for either top-
ical or systemic drug administration. Beside these, the etho-
somal carrier was also capable of providing an eﬃcient intra-
cellular delivery of both hydrophilic and lipophilic molecules
[14] and the permeation of an antibiotic peptide [15].
Consequently, the aim of the present study was to
develop topical ethosome of tacrolimus and to evaluate it
with respect to various in vitro experiments. In this paper,
ethosomes with phospholipids and ethanol were prepared2 The Scientiﬁc World Journal
and evaluated for particle size, polydispersity index (PDI),
and drug entrapment eﬃciency (EE) to investigate the
potential application of ethosomes for dermal delivery of
tacrolimus. The percutaneous permeation of tacrolimus-
loaded ethosomes through SC and epidermis membranes
was evaluated in vitro and was compared with those of
drug-loaded classical liposomes. Further, the stability of
tacrolimus-loaded ethosomes was investigated.
2.MaterialsandMethods
2.1. Chemicals and Reagents. Lipoid S 100 containing
more than 94% phosphatidylcholine from soybean lecithin
was purchased from Lipoid Co (Ludwigshafen, Germany).
Tacrolimus powder was provided from Taishan Chemical
Pharmaceutical Co., LTD (Taishan, China). Protopic oint-
ment was purchased from Astellas Pharma Manufacturing,
Inc. (Grand Island, NY, USA). All other chemicals were of
analytical grade and used as received.
2.2. Animals. Sprague-Dawley (SD) rats weighing 200 ± 20g
were obtained from Animals Center of Peking University
Health Science Center. All care and handling of animals were
performed with the approval of Institutional Authority for
Laboratory Animal Care of Peking University and followed
the principles in the Declaration of Helsinki.
2.3. Preparation of Tacrolimus Ethosomes and Liposomes.
Ethosomes were prepared from 2% w/v Lipoid S 100, 30%
v/v ethanol, 0.1% w/v tacrolimus, and water as described
previously [13]. Brieﬂy, Lipoid S 100 was added into a glass
vialandsolubilized with ethanol. Theglass vialwassealedup
completely and connected with a tube to a syringe system to
allow the addition of water and to avoid ethanol evaporation
asfaraspossible.Followingthesolubilizationoflipoid,water
was added to obtain the ethosomal colloidal suspensions,
which was agitated for almost 5min at 50◦C. Liposomes
loading tacrolimus were prepared by the conventional thin-
ﬁlm hydration method. Generally, Lipoid S 100 for ﬁnal
concentration of 2% w/v and tacrolimus were dissolved
in methylene chloride, respectively. Drug was added to
furnish the desired concentration in the ﬁnal formulation
(0.1%, w/v). Then organic solvent was removed by rotary
evaporation vacuum, and deposited lipid ﬁlm was hydrated
with water by rotation (nearly 100rpm) for 30min at room
temperature. Finally, liposomal suspensions were sonicated
in a bath-type sonicator for 20min at 5◦C for particle
homogenization, and then the optically clear suspension was
ﬁltered through a 0.22mm Millipore ﬁlter for three cycles.
2.4. Particle Size Distribution. For the ethosomal colloidal
suspension,themeansizeandthepolydispersityindex(PDI)
used as a parameter of the size distribution were measured
by dynamic laser light scattering (DLS) with a helium-
neon laser at 630nm (Zetasizer, Malvern, UK). In order to
avoid multiscattering phenomena the samples were ﬁltered
through 0.45µm membrane ﬁlters. The determination was
repeated three times per sample.
2.5. HPLC Assay for the Determination of Tacrolimus Con-
tent. Quantitative analysis of tacrolimus in ethosomal and
liposomal formulations was performed by HPLC. An ODS-
Hypersil C18 (250mm × 4.6mm i.d., 5-µmp a r t i c l es i z e )
chromatographic column was used. The mobile phase was
a mixture of acetonitrile/water (7:3, v/v). HPLC apparatus
(Shimadzu, Tokyo, Japan) was performed isocratically at
60◦C and a ﬂow rate of 1mL/min with UV detection
at 215nm. Every sample was ﬁltered through a 0.45µm
membrane ﬁlter prior to analysis.
2.6. Entrapment Eﬃcacy of Ethosomes. The drug-entrapment
percentage was determined by two methods: ultraﬁltration
and dialysis method. At ﬁrst, unbound tacrolimus was
isolated by ultraﬁltration on Amicon MPS (Millipore, USA)
units using the YM-10 membranes (Millipore, USA) of
10kDa molecular mass cutoﬀ. 400µL of ethosomal or
liposomal solution was put into a sample compartment of
the ultraﬁltration unit. Then the unit was centrifuged using
a TCL-16G Centrifuger (Shanghai, China) at 10,000rpm
(14,000 ×g) after the attachment of an ultraﬁltrate collection
container. The ﬁltrate was taken out, and the drug amount
was determined by HPLC. The entrapment eﬃciency (EE)




where DE was the amount of tacrolimus determined in the
ethosome or liposome and DS was the amount of drug
determined in the ﬁltrate. The results were expressed as a
mean value of three times.
At the same time, the drug EE determination was also
determinedbydialysismethod.Celluloseacetatemembranes
(MWCO 12,000–14,000) were kept into 30% v/v alcoholic
solution for 1h before dialysis to ensure the whole wetting
of the membrane; 2mL of the drug-loaded ethosomes were
placed into the dialysis bag which was then transferred into
30mL of 30% v/v alcoholic solution. Samples of 1mL were
withdrawnfromthereceivermediumstirredwithamagnetic
stirrerandreplacedwithequalvolumesofalcoholicsolution.
Samples were analyzed by HPLC. In this case, the EE was
calculated from the same equation described above based on
the result analysed by HPLC.
2.7. Quantiﬁcation of Drug in Diﬀerent Skin Strata. Skin
s a m p l e sw e r eo b t a i n e df r o mm a l eS Dr a t sw e i g h i n g1 8 0t o
220g. After hair was shaven using a mechanical hair clipper,
a3× 3cm patch of skin was cut oﬀ from the abdominal
region of rat without damaging skin, and then the adhering
fat and visceral tissue were removed carefully. The excised rat
skin was stored at −20◦C and used within one week after
harvesting. Skin permeation studies were performed using
Franz-type diﬀusion cells [16] with a diﬀusional surface area
of 2.5cm2 and a volume of 12mL, respectively. Skin was
mounted horizontally with the stratum corneum side up
onto the donor compartment. The receptor was ﬁlled with
pH 7.4 isotonic PBS continuously stirred with a magnetic









































Figure 1: Particle size distribution of tacrolimus liposomes (a) and ethosomes (b) by dynamic laser light scattering.
(2mL) was applied in the donor compartment sealed with
paraﬁlm in order to obtained occlusive conditions; the
amount was suﬃcient to maintain steady state conditions.
The time of duration for the experiments was 48h. At the
end of 48h the excess formulation from the surface of the
skin was absterged. The stratum corneum (SC) layer from
the skin was removed by stripping with an adhesive tape,
and the epidermis was separated from the dermis using heat
separation technique [17]. The tacrolimus in each of the skin
layers SC and epidermis was extracted with methanol, and
the amount of drug was quantiﬁed in the same method as
HPLC.
2.8. Stability of Ethosomes under Storage Condition.
Tacrolimus-loaded ethosomes (0.1%, w/v) were displaced
into the amber glass and were preserved at 4◦Cf o r9 0d a y s .
At predetermined time intervals, samples were transferred
into a clear test tube for visual observation; the stability of
samples was monitored by the time-dependent changes in
the physical characteristics, particle size, and EE during the
storage period. The experiments were performed in three
replicates.
2.9. Statistical Analysis. A l ld a t aw e r ee x p r e s s e da sm e a n±
standard deviation (SD) unless particularly outlined. The
statistical signiﬁcance of diﬀerences among more than two
groups was determined by one-way ANOVA using the
softwareSPSSforWindowsversions13.0.AvalueofP<0.05
was considered to be signiﬁcant.
3. Results
In the present study, the properties of tacrolimus-loaded
ethosomes in terms of size, structure, entrapment eﬃciency
(EE), and amount of tacrolimus in diﬀerent skin strata in
comparison to tacrolimus-loaded liposomes were examined.
3.1. Preparation and Characteristics of Ethosomes. Particle
size aﬀected topical drug delivery; drug-loaded formulation
with average diameters below 300nm could be delivered to
some extent into deeper layers of the skin [18, 19]. In the
cases of ethosomes and liposomes with particle size lower
than 200nm, there was the potential for permeation through
the skin. It was shown from Table 1 and Figure 1 that the
particlesizeoftheethosomalsystemwassigniﬁcantlysmaller
Figure 2: Transmission electron microphotography of tacrolimus
ethosomes.
Table 1: Physicochemical characteristics of tacrolimus-loaded
liposomes and ethosomes.
Liposomes Ethosomes
Particle size (nm) 146 ± 12 85 ± 13∗
Polydispersity index 0.268 ±0.051 0.298 ±0.024
Entrapment eﬃciency (%) 65.3 ±2.27 8 .7 ±3.3∗∗
∗P<0.05; ∗∗P<0.01 versus liposomes.
than that of the liposomal system (P<0.05). Moreover,
polydispersity index (PDI) representing the distribution of
particle size was below 0.3 indicating narrow size distribu-
tion.
Zeta potential including its ionic atmosphere was the
electric potential of the vesicle. Blank ethosomes exhibited a
negative charge of −4.3mV, while the addition of only 0.1%
w/w tacrolimus shifted the vesicle charge from negative to
positive (+4.8mV). Further increase of the tacrolimus con-
centration in the ethosomal system caused a corresponding
increaseinvesicularcharge(datanotshown).Incomparison,
0.1% w/w tacrolimus had no eﬀect on the charge of classic
liposomes.
For an initial vesicle characterization, ethosomes was ex-
amined by TEM. In all cases, the presence of spherical-
shaped vesicles was prominent (Figure 2). Moreover, sam-
ples exhibited some vesicle aggregates in the vision ﬁeld.4 The Scientiﬁc World Journal
The cause was that the absence of cholesterol in the formu-
lations was beneﬁcial to the aggregation process among the
structures which was proved by other studies [20, 21], on
account of cholesterol eﬀect as stabilizing agent in the lipid
bilayer.
3.2. Determination of the Tacrolimus Content by HPLC. The
standard curve of tacrolimus in methanol was shown to
be linear (r2 = 0.9993) over the concentration range
0.02–1.50µg/mL. The following regression equation was
obtained: A = 12697C − 6615, where A is the peak area of
tacrolimusandC istheconcentrationoftacrolimus(µg/mL).
Prior to the study, all related blank samples (alcoholic
solution, lipoid S100 in methanol) were analyzed by HPLC.
The result indicated that the retention time of tacrolimus
chromatograph was 15min under this condition, while the
resulting HPLC chromatograms of alcoholic solution and
lipoid S 100 showed no peaks eluted from 14 to 15min.
Thus, there was no interference on the determination of
tacrolimus content by HPLC caused by these blank samples.
Besides, accuracy ranged from 101.2% to 105.0% for all
samples, and precision was below 2.0, indicating that the
system was reliable for analysis. The recovery range and RSD
for all samples were found to be 98.0%–101.5% and 1.1%–
1.7%, respectively. Thus, acceptable results with respect to
precision (RSD < 2%) were obtained for all analytes.
3.3.EntrapmentEﬃciency. Thereweretwodiﬀerentmethods
such as ultraﬁltration and dialysis used to quantify the
tacrolimus amount entrapped into the systems. EE deter-
mined with the ultraﬁltration method was (78.7 ± 3.3)%
which was slightly lower than that with the dialysis method
(80.4 ± 4.4)%. The result suggested a losing of entrapped
drug during the ultraﬁltration process probably due to the
deformation phenomenon of lipid membranes caused by the
high speed reached with this method. As a result, based on
no signiﬁcant diﬀerence in EE between above two methods
(P>0.05), ultraﬁltration method was chosen due to longer
period for dialysis method.
As shown in Table 1, ethosomes and liposomes exhib-
ited an entrapment eﬃciency of about 78.7% and 65.3%,
respectively, indicating that solubility of the drug in the
medium might inﬂuence the entrapment capacity of vesicles.
In liposomes, tacrolimus as a highly lipophilic molecule was
only in the bilayer and did not enter the aqueous core. It was
assumed that the core and membrane of the ethosome were
saturated with medium, which might allow for tacrolimus to
be distributed throughout the vesicle, as opposed to only the
bilayer with liposomes.
3.4.QuantiﬁcationofDruginDiﬀerentSkinStrata. Asshown
in Figure 3, the amounts of tacrolimus for ethosomes and
liposomes were signiﬁcantly higher than that for Protopic
ointmentwhetherinSCorepidermis(P<0.001),suggesting
that two vesicular formulations might improve drug distri-
bution in deeper skin with AD. Relatively, the amount of
tacrolimus for ethosomes was lower than that for liposomes
in SC (P<0.05) and was signiﬁcantly higher than that for
Table 2: The stability of tacrolimus-loaded ethosomes under
storage condition (4◦C).
0m o n t h 3m o n t h
Particle size (nm) 85 ± 13 96 ± 11ns
Polydispersity index 0.298 ±0.024 0.312 ±0.031ns
Entrapment eﬃciency (%) 78.7 ±3.37 4 .3 ±4.5ns

















































Figure 3: The amount of tacrolimus in stratum corneum and
epidermis for tacrolimus formulations.
liposomes in epidermis (P<0.001), indicating that more
amount of drug within ethosomes would permeate into
more deeper epidermis as compared with liposomes, which
suggested stronger pharmacological eﬀect for ethosomes.
3.5. Stability under Storage Condition. The stability of inves-
tigated systems was determined by comparing the physical
appearance, average size, PDI, and EE over time. Table 2
presented the stability of ethosomes kept at 4◦Ca n d
measured at various time intervals after preparation. It was
shownthattacrolimus-loadedethosomalsystemresultedina
slight increase of particle size and PDI at 3 months (P>0.05,
versus 0 month), and neither precipitation nor drug crystals
wereobserved,indicatingthattheethosomeswerestillintact.
Moreover,EEdidnotaltersigniﬁcantlyafterstorageforthree
months attributed to that the oxidation and hydrolysis of
the lipids caused in decomposition and aggregation of the
liposome vesicles, drug leakage, and slight decrease in the
zeta potential at room temperature were inhibited at low
temperature.
4. Discussion
According to the physicochemical characteristics of
tacrolimus-loaded vesicular formulations (particle size
and PDI), as shown in Table 1 and Figure 1,i tw a ss u g g e s t e d
that ethanol had a ﬂuidizing eﬀect on phospholipid bilayersThe Scientiﬁc World Journal 5
[13,22]ascomparedwithcommonliposomes.Furthermore,
ethanol probably caused an alteration of the net charge of
the system and conferred it some extent of steric stabilization
that might ﬁnally lead to a reduction in the mean particle
size [23, 24]. In other words, ethanol had a predominant
role in ethosomal systems since introducing ethanol to
conventional liposomes produces tender, compact, and
transformable vesicles [22].
Ethosomal systems with interdigitated ﬂuid bilayers
are novel permeation-enhancing lipid carriers. It has been
shown that ethosomes exhibit high encapsulation eﬃciency
for a series of lipophilic molecules and deliver eﬀectively
drugs to and through the skin [13, 25, 26]i nc o n t r a s tt o
classic liposomes. The results (Figure 3.) showed that the
drug encapsulation within ethosomes or liposomes could
inﬂuencepositivelythepermeationofamoleculethroughSC
to some degree, although the real contribution was diﬃcult
to evaluate due to the deformable and permeable nature of
ethosomes which allowed the rapid drug diﬀusion from the
environment into ethosome compartments. These ﬁndings
might be attributed to some reasons as below: ﬁrst, the
stratum corneum (SC) lipid multilayers were highly con-
formationally ordered and densely packed at physiological
temperature. Ethanol might interact with lipid molecules
in the polar headgroup region inducing a reduction in
the Tm of the SC lipids. Thus the organization of the SC
lipid bilayer was disturbed, and their ﬂuidity was enhanced.
Second,theintercalationofethanolintothepolarheadgroup
environment could lead to an increase in the membrane
permeability [27, 28]. That is to say, ethosomal lipids were
in a more ﬂuid state than liposomes containing the same
ingredients without ethanol. These data are supported by
previous reports that ethanol generally has a ﬂuidizing eﬀect
on phospholipid bilayers [29]. In contrast to liposomes,
ethosomesarelessrigid[30].Therefore,theeﬀectsofethanol
might give the vesicles soft ﬂexible characteristics to more
easily penetrate into deeper layers of the skin, although it
was considered harmful to classic liposomal formulation.
The third contribution to the high skin penetration from the
ethosomalsystemcouldhaveconnectionwiththeinteraction
between ethanol together with phospholipid vesicles and SC
which was also proposed by Kirjavainen et al. [31]. It has also
been suggested that mixing of phospholipids with SC lipids
of the intercellular layers enhanced the permeability of the
skin [32]. In summary, the eﬀect of ethanol on SC lipids and
on vesicle ﬂuidity as well as a dynamic interaction between
ethosomes and SC might contribute to the superior delivery
properties described here. While tacrolimus encapsulated in
classic ointment remained primarily at the surface of the
skin, the ethosomal system was shown here to be a highly
eﬀective carrier for enhanced tacrolimus delivery to deeper
layers of the skin.
5. Conclusion
In this paper, liposome and ethosome formulations con-
taining tacrolimus as a lipophilic drug have been prepared
successfully and characterized. It was observed that the
presence of ethanol in the aqueous compartment of the
vesicles favoured tacrolimus encapsulation. Therefore, the
inclusion of ethanol in liposomes might play a vital role
in the enhancement of tacrolimus permeation. The eﬃcient
drug delivery shown here together with the long-term sta-
bility of ethosomes made this system a promising candidate
for topical delivery of tacrolimus. Currently, further studies
involving safety on skins, pharmacological eﬀect on AD, and
mechanism of inhibition action for the ethosomal delivery
systems were being performed.
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